How much funding has Antengene raised?

Antengene has raised $238.0M in total funding, most recently a Series C round.

Who are Antengene's investors?

Antengene's investors include Fidelity Management, Boyu Capital, FountainVest Partners, Qiming VP, Hong Kong Stock Exchange, GL Ventures.

Where is Antengene headquartered?

Antengene is headquartered in Shanghai, China.

What industry is Antengene in?

Antengene operates in Biotech, Oncology, Healthcare.

How many employees does Antengene have?

Antengene has 201-500 employees.

Antengene

IPO

Public · Shanghai, China · Founded 2017 · $238.0M raised

Biotech

Oncology

Healthcare

Headquarters: Shanghai
Employees: 201–500
Founded: 2017
Business Model: B2B
Website: antengene.com

Total Funding: $238.0M
Last Round: $97.0M Series CJul 2020
Rounds: 3
Type: Public

About

Antengene Corporation Limited (SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class and best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, including ADCs, bispecific antibodies, and T cell engager programs developed on the proprietary AnTenGager® platform. Lead commercial asset XPOVIO® (selinexor) is approved in 10 Asia Pacific markets.

Summary

Antengene is a Biotech company based in Shanghai, China, founded in 2017. It has raised $238.0M in total across 3 rounds, most recently a $97.0M Series C round in Jul 2020. Investors include Fidelity Management, Boyu Capital and FountainVest Partners.

LinkedIn X (Twitter)